Discontinued — last reported Q4 '22
Business Segments · Other Assets
Corporate Segment — Other Assets
Boston Scientific Corporate Segment — Other Assets decreased by 21.0% to $5.94B in Q4 2022 compared to the prior quarter.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ4 2019
Last reportedQ4 2022
Rolls up toOther Assets
How to read this metric
An increase may indicate higher investment in shared corporate infrastructure or a buildup of centralized cash, while a decrease might suggest the allocation of assets to specific operating segments or the divestiture of non-core holdings.
Detailed definition
This metric represents the book value of assets held within the corporate segment that are not directly attributable to...
Peer comparison
Most large-cap medical device companies report similar 'Corporate' or 'Unallocated' asset pools, though the composition varies based on the degree of centralization in R&D and administrative functions.
Metric ID:
bsx_segment_corporate_segment_other_assetsHistorical Data
2 periods
| Q4 '21 | Q4 '22 | |
|---|---|---|
| Value | $7.53B | $5.94B |
| QoQ Change | — | -21.0% |
| YoY Change | — | -21.0% |
Range$5.94B – $7.53B
Avg YoY Growth-21.0%
Median YoY Growth-21.0%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Boston Scientific's corporate segment — other assets?
- Boston Scientific (BSX) reported corporate segment — other assets of $5.94B in Q4 2022.
- What does corporate segment — other assets mean?
- The value of assets held at the corporate level that are not assigned to any specific business division.